References

Review of venetoclax in CLL, AML and multiple myeloma

10.3390/jpm11060463 · 2021 · External reference

Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia

10.1056/nejmoa1513257 · 2016 · External reference

Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial

10.1200/jco.2017.76.6840 · 2018 · External reference

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

10.1182/blood.2018882555 · 2019 · External reference

Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy

10.1182/blood.2020009578 · 2021 · External reference

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

10.1016/s1470-2045(20)30443-5 · 2020 · External reference

Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities

10.1056/evidoa2200006 · 2022 · External reference

Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia

10.1056/nejmoa2409804 · 2025 · External reference

Fixed-duration versus continuous treatment for chronic lymphocytic leukemia

10.1056/nejmoa2515458 · 2026 · External reference

First-line venetoclax combinations in chronic lymphocytic leukemia

10.1056/nejmoa2213093 · 2023 · External reference

MURANO: final 7 year follow up and retreatment analysis in venetoclax-rituximab (VenR)-treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)

10.1002/hon.3163_156 · 2023 · External reference

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

10.1182/blood.2021015014 · 2022 · External reference

The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL

10.1182/blood.2024025525 · 2025 · External reference

BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax

10.1182/blood.2020004782 · 2020 · External reference

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

10.1182/blood.2024024631 · 2024 · External reference

Venetoclax and obinutuzumab in patients with CLL and coexisting conditions

10.1056/nejmoa1815281 · 2019 · External reference

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial

10.1182/blood.2025032160 · 2026 · External reference

Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia

10.1182/bloodadvances.2023011741 · 2024 · External reference

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

10.1182/bloodadvances.2022007812 · 2022 · External reference

MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma

10.2217/fon-2022-0456 · 2022 · External reference

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial

10.1016/s1470-2045(23)00144-4 · 2023 · External reference

Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma

10.1056/nejmoa1715519 · 2018 · External reference

Azacitidine and venetoclax in previously untreated acute myeloid leukemia

10.1056/nejmoa2012971 · 2020 · External reference

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

10.1016/s1470-2045(17)30012-8 · 2017 · External reference

Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial

10.1080/10428194.2021.1986217 · 2022 · External reference

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

10.1182/blood-2017-09-806398 · 2018 · External reference

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy

10.1002/jha2.177 · 2021 · External reference

Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study

10.1200/jco.20.00948 · 2020 · External reference

Revisiting Richter transformation in the era of novel CLL agents

10.1016/j.blre.2021.100824 · 2021 · External reference

Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax

10.1182/blood-2017-01-763003 · 2017 · External reference

Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy

10.1002/ajh.26411 · 2022 · External reference

Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia

10.3324/haematol.2019.222588 · 2019 · External reference

Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed/refractory chronic lymphocytic leukemia

10.1158/1078-0432.ccr-17-3761 · 2018 · External reference

Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies

10.1038/s41375-019-0481-1 · 2019 · External reference

Long-term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab

10.1002/hem3.146 · 2024 · External reference

Second cancer incidence in CLL patients receiving BTK inhibitors

10.1038/s41375-020-0987-6 · 2020 · External reference

Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study

10.1182/bloodadvances.2023010236 · 2023 · External reference

Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy

10.1038/leu.2010.218 · 2010 · External reference

Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL

10.1182/blood.2021012775 · 2022 · External reference

Ot02 | Cll18/Moirai trial aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes in treatment-naive Cll/Sll

10.1002/hon.70093_ot02 · 2025 · External reference